54186-71-9Relevant articles and documents
Quinoxaline compound, preparation method and application of quinoxaline compound in medicine
-
Paragraph 0102-0105; 0324-0326; 0328, (2021/07/24)
The invention provides a quinoxaline compound, a preparation method and application of the quinoxaline compound in medicine, and particularly relates to a quinoxaline compound with PAR4 antagonistic activity, a preparation method of the quinoxaline compound, a pharmaceutical composition containing the quinoxaline compound and application of the quinoxaline compound. Specifically, the invention provides a compound shown as a general formula I and/or II or a tautomer or pharmaceutically acceptable salt thereof, a preparation method of the compound, and application of the compound or the tautomer or the pharmaceutically acceptable salt in medicines for preventing and/or treating thromboembolic diseases.
Copper Complexes of New Redox-Active 4,5-Bisguanidino-Substituted Benzodioxole Ligands: Control of the Electronic Structure by Counter-Ligands, Solvent, and Temperature
Schrempp, David Fridolin,Kaifer, Elisabeth,Wadepohl, Hubert,Himmel, Hans-J?rg
, p. 16187 - 16199 (2016/10/30)
Herein, we analyze the possibility of controlling the electronic structure of mononuclear copper complexes featuring new redox-active 4,5-bisguanidino-substituted benzodioxole ligands. The nature of the guanidino groups, the anionic counter-ligands, the applied solvent (polarity), and the temperature are the parameters that decide if a CuIIcomplex with neutral ligand unit or a CuIcomplex with radical monocationic ligand unit is the adequate description. Under special conditions, a temperature-dependent equilibrium of the two valence tautomeric forms (CuII/neutral ligand and CuI/radical monocationic ligand) is achieved. Removal of a ligand-centered electron from a paramagnetic CuIIcomplex with a neutral ligand unit leads to a diamagnetic CuIcomplex with a dicationic ligand unit through a redox-induced electron-transfer (RIET) process.
Heteroaroylhydrazide derivatives of monocyclic beta-lactam antibiotics
-
, (2008/06/13)
Compounds having the formula STR1 and pharmaceutically acceptable salts thereof and possessing antibacterial activity, and intermediates to compounds of formula I having the formula